AGC Biologics will commence cell therapy process development and clinical manufacturing services on July 1 at AGC Inc.’s ...

Cellular Origins has entered into a collaboration with Johnson & Johnson to develop a scalable, end-to-end automated platform ...

The safety and efficacy outcomes of a total of 3 CD19-directed CAR T-cell therapies were confirmed with other real-world data ...

The most prevalent toxicity seen in patients who receive CAR T-cell therapy is CRS, which is a systemic inflammatory response that results from a potent production of inflammatory cytokines and ...

In modern immunotherapy, modified immune cells are introduced into the body to attack tumors and other targets. Researchers ...

Innovative immunotherapy shows promise against aggressive T cell cancers WashU startup's 'off-the-shelf' CAR-T cell therapy evaluated in international clinical trial ...

A dual-target CAR T cell therapy approach shows promise for slowing tumor growth in a notoriously aggressive and fast-growing brain cancer. Tumors became smaller after the experimental CAR T cell ...

How specialized expertise, advanced infrastructure, and strategic partnerships are enabling the next generation of cell-based ...

Studies of MUC-1-CAR T (NCT03525782) and ROR1-CAR T (NCT02706392) in 28 NSCLC patients showed similar outcomes. For MUC1-CAR T in 20 patients, 11 had SD, and 9 developed PD. In the ROR1-CAR T study ...

In all three models, in vivo gene transfer led to significant therapeutic benefits, prolonging life. Notably, in Fanconi anemia, corrected stem cells progressively repopulated the blood system and ...

A Gilead Sciences-backed therapy made with a patient's own white blood cells shrank tumors in 62% of patients with recurrent glioblastoma, a rare event for a fatal brain cancer with few treatment ...